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Abstract
The win ratio is a general method of comparing locations of distri-
butions of two independent, ordinal random variables, and it can be es-
timated without distributional assumptions. In this paper we provide a
unified theory of win ratio estimation in the presence of stratification and
adjustment by a numeric variable. Building step by step on the estimate
of the crude win ratio we compare corresponding tests with well known
nonparametric tests of group difference (Wilcoxon rank-sum test, Fligner-
Plicello test, Cochran-Mantel-Haenszel test, test based on the regression
on ranks and the rank ANCOVA test). We show that the win ratio gives
an interpretable treatment effect measure with corresponding test to de-
tect treatment effect difference under minimal assumptions.
Keywords: Win ratio, win probability, location test, stratification, adjust-
ment, Wilcoxon test, Cochran-Mantel-Haenszel test, van Elteren test, Fligner-
Policello test, Hodges-Lehmann estimator, rank analysis, rank ANCOVA, esti-
mand, intercurrent event, clinical trial, missing data, DAPA-HF, heart failure,
KCCQ, PRO, symptom score, NNT.
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1 Introduction
The win ratio as a measure for analyzing clinical endpoints was suggested
in [Pocock et al. (2012)], [Wang et al. (2016)] to handle composite endpoints
where the components are not clinically equivalent. For example, in heart failure
(HF) trials the primary endpoint of interest is usually time to the composite of
cardiovascular death (CVD) or a heart failure hospitalization (HFH), whichever
happens first for an individual. By combining these two into one composite end-
point, we disregard the fact that a hospitalization for heart failure is clinically
different from cardiovascular death. To overcome this issue an order is intro-
duced between the components of the composite endpoint and it is analyzed as
an ordinal variable. The win ratio intends to introduce an appropriate statisti-
cal approach to analyze such endpoints. The idea is to compare the outcomes
from two distributions and assign the values “win”, “loss” or “tie” to these com-
parisons based on the value of the distribution of interest being correspondingly
“better”, “worse” or “equal” to the value from the other distribution. The ad-
vantage of such approach is that in very general situations a comparison can
be defined. For example, if subjects are followed an equal period of time until
an HFH or a CVD happens, an order can be introduced by treating censoring
as being better (in terms of benefit to patients) than HFH which in turn is
better than CVD, while subjects experiencing an event of the same type can
be compared using the time of the event (later is better). Hence two groups of
patients receiving different treatments can be compared using this ordering, and
the benefit of one treatment against the other can be estimated using the win
ratio. Recent years saw more applications of win ratio in clinical trials as a part
of prespecified testing hierarchy. To give two examples, the recently announced
EMPULSE trial (registration number NCT04157751 in ClinicalTrials.gov) is a
multicentre, randomized, double-blind, 90-day superiority trial in patients hos-
pitalized for acute heart failure, where the primary endpoint is defined as a
hierarchical composite of time to death, number of HF hospitalizations, time to
first HFH and change in a KCCQ-CSS (clinical summary score of the Kansas
City cardiomyopathy questionnaire) from baseline after 90 days of treatment
(see Section 2.5). On the other hand, a large-scale CV (cardiovascular) out-
come trial DAPA-HF (registration number NCT03036124 in ClinicalTrials.gov)
in patients with heart failure with reduced ejection fraction (HFrEF) used the
win ratio for analyzing patient reported symptoms scores as the third secondary
endpoint. Application of the win ratio approach in the DAPA-HF trial will be
the central topic of the Section 5.
In parallel, statistical methods for analyzing the win ratio started to gain
more attention. In [Pocock et al. (2012)] a confidence interval was constructed
only for the so-called matched win ratio, which uses a restrictive definition of the
win ratio. For the general definition of the win ratio, [Wang et al. (2016)] con-
structed a confidence interval using the bootstrap approach. [Dong et al. (2016)]
gave an analytical approach for construction of a confidence interval and cor-
responding hypothesis testing using logarithmic asymptotic distribution of the
win ratio. In subsequent papers, the authors provided generalization of the win
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ratio for the stratified analysis in [Dong et al. (2018)], interpretation of the win
ratio (including the definition of estimands for the win ratio as described in ICH
E9 (R1) addendum on estimands) and handling of ties in [Dong et al. (2019)].
The papers [Luo et al. (2015)], [Luo et al. (2017)] derive an alternative stan-
dard error estimate for the win ratio using counting process methods. Usu-
ally in the time-to-event setting the follow-up time and the outcome at the
end of the follow up are used to define the ordering, as was initially described
in [Pocock et al. (2012)], which means that the censoring is not used in the
traditional sense of having incomplete observations. [Oakes (2016)], following
[Efron (1967)], introduces a win ratio estimate for the censored observations. In
our setting, time will be fixed and will not be used in defining the order between
the outcomes.
Almost all existing analytical solutions for the standard error estimation
for the win ratio use the theory of U-statistics developed in the seminal pa-
per [Hoeffding (1948)], and the relationship of the win ratio and the Mann-
Whitney test statistic is apparent (see [Bebu et al. (2015)]). In this article
we will further explore this relationship and will reformulate the results of
the generalized Mann-Whitney statistic (stratified and adjusted for a numeric
baseline covariate), developed extensively in the papers [Davis et al. (1968)],
[Puri et al. (1971)], [Landis et al. (1978)], [Koch et al. (1982)], [Koch et al. (1998)],
[Kawaguchi et al. (2011)], to account for this new change in concepts.
The win ratio is defined as an odds of the win probability. First, the win
probability is introduced as the theoretical probability of one, in general, ordinal
random variable being greater than a second ordinal random variable under
the condition that these random variables are independent. Several examples
illustrate how this theoretical probability can be calculated if the underlying
distributions of these random variables are known. Then a crude estimate of
the win probability, called win proportion, is introduced, and a simulation shows
the convergence of the win proportion to the win probability. Building step-by-
step on the crude win proportion, continuous baseline covariate adjustment and
stratification is introduced. In each step, the test based on the win probability is
compared with well-known tests for group difference (Wilcoxon rank-sum test,
Fligner-Plicello test, Cochran-Mantel-Haenszel test, test based on the regression
on ranks and the rank ANCOVA test).
Outline Section 2 gives the the definition of the win probability, its inter-
pretation, the estimation and the construction of confidence intervals. In this
section we also discuss the applied problem where the win ratio approach can
be used. Section 3 generalizes the win proportion for the stratified analysis and
adjustment with a numeric covariate. Section 4 compares the tests based on the
win probability with other non-parametric tests. Section 5 applies the theory
to the analysis of symptoms scores in DAPA-HF landmark trial.
4
2 Win probability (WP)
In this section we will define and investigate the properties of the non-adjusted
(crude) win probability. Non-adjusted in our setting means that we observe
only the response variables without predictors. In the following sections, the
analysis time is fixed.
Suppose we have two groups of subjects receiving different treatments. The
first group receives placebo, the second group receives an active treatment. At
some prespecified timepoint a measurement for the primary variable of interest
is done and the following values are obtained
Y1 = (y11, · · · , y1n1), Y2 = (y21, · · · , y2n2) (1)
where n2 is the number of subjects in the active treatment group and n1 is
the number of subjects in the placebo group. We consider only the case when
only a single measurement per subjects is done and there are no missing values.
The measurement values are, in general, ordinal - they have a natural ordering,
that is, the values can be compared, but, unlike the numeric values, there is
no distance defined between values. We take the convention that higher values
correspond to better outcome. We assume that y2j , j = 1, · · · , n2 are an
i.i.d. (independent and identically distributed) sample from the distribution of
the random variable η and y1i, i = 1, · · · , n1 are an i.i.d sample from ξ. We
additionally require that η and ξ be independent.
2.1 Definition and interpretation of WP
To characterize the treatment effect of the active group in comparison to the
placebo group we introduce the “win probability” of the active treatment against
the placebo as
P(η > ξ). (2)
In this case P (η > ξ) > 12 favors the active treatment, whereas P (η > ξ) <
1
2
favors placebo, with no treatment difference in the case of P (η > ξ) = 12 . Our
goal will be to test the hypothesis of whether there is a treatment effect difference
between the active group and the placebo group based on the win probability.
Before proceeding with the statistical analysis, we describe an example of how
the win probability can be interpreted.
Example 2.1. Suppose that ξ has a uniform distribution ξ ∼ U[0, a], a > 0. The
random variable η is independent of ξ and has a uniform distribution, shifted
by a non-negative number δ (0 ≤ δ ≤ a), that is η ∼ U[δ, a+ δ]. Then, it follows
that
P(η > ξ) =
1
2
+
(2a− δ)δ
2a2
.
If δ = 0, meaning that the random variables have the same distribution U[0, a],
then P(η > ξ) = 12 . Figure 2.1 below shows the probability density function
5
(pdf) of the random variable η − ξ in the case when δ = 0. The probability
P(η − ξ > 0) is the area under the curve to the right of the origin. The pdf is
symmetric, therefore the probability of the difference being positive is 12 .
Figure 2.1: Difference of i.i.d. uniform random variables
If 0 < δ < a, then the pdf of η−ξ will be shifted to right by δ. The probability
P(η − ξ > 0) will be the grey area in Figure 2.2, which is 12 plus the area of the
trapezoid over the interval [0, δ], calculated as
P(η > ξ) =
1
2
+
1
2
δ
(
a− δ
a2
+
1
a
)
=
1
2
+
(2a− δ)δ
2a2
.
Figure 2.2: Difference of uniform distributions - shifted
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Remembering that δ = E(η − ξ), we see that the difference between the win
probability and 12 is the difference in probability corresponding to the change from
0 of the mean difference of random variables. So, the mean difference δ ∈ [0, a]
of random variables corresponds to the following deviation of the win probability
from 12
P(η > ξ)− 1
2
=
(2a− δ)δ
2a2
.
We see that there is a quadratic increase in the win probability, which will attain
its maximal value for the shift δ = a. In the latter case P(η > ξ) = 1, since the
intervals where the densities are not 0 are completely separated and the density
of η is entirely to the right of the density of ξ. Hence the win probability gives
a quantitative probabilistic interpretation to the mean difference.
In Example 2.1 we had two identically distributed random variables, one of
which had shifted mean value. The next example shows that the same interpre-
tation is true for normally distributed random variables, even if the variance of
random variables is different as well.
Example 2.2. Suppose that ξ ∼ N (m1, σ21) and η ∼ N (m2, σ22) are indepen-
dent, normally distributed random variables. Then η−ξ ∼ N (m2−m1, σ21 +σ22).
The probability P(η > ξ) is the grey region in Figure 2.3 below (shown for the
case m2 > m1),
Figure 2.3: Difference of two normal distributions
and it can be calculated using the formula
P(η > ξ) = Φ
(
m2 −m1√
σ21 + σ
2
2
)
, (3)
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where Φ(·) is the distribution function of the standard normal random variable.
For example, in the case of ξ ∼ N (0, 1) and η ∼ N (1, 1), we have P(η > ξ) =
0.76, and when ξ ∼ N (0, 1) but η ∼ N (1, 4), then P(η > ξ) = 0.67. The latter
shows that the increase of variance in one of the random variables reduces the
win probability.
Remark 2.1. The random variable ζ is called symmetric if it has the same
distribution as −ζ. The median of the distribution of the random variable ζ is
defined as any number µ satisfying the inequalities
P(ζ ≥ µ) ≥ 1
2
and P(ζ ≤ µ) ≥ 1
2
.
The following statements immediately follow from the definitions above.
1. If ζ has a continuous distribution and a unique median µ0, then
P(ζ > µ0) =
1
2
.
2. If ζ has a continuous distribution which is symmetric, then
P(ζ > 0) =
1
2
.
3. For all continuous, identically distributed random variables ξ and η, the
win probability is equal to P(η > ξ) = 12 . Indeed, since ζ = η − ξ is
symmetric, then the win probability of both random variables will be 12 .
Using Remark 2.1, Examples 2.1, 2.2 can be generalized as follows.
Example 2.3. Suppose that the independent random variables ξ and η have
continuous distributions.
1. If there is a real number δ such that the random variable
ζ = η − ξ − δ
is symmetric, then
P(η > ξ + δ) =
1
2
.
Hence the equality of the win probability to 12 , that is, θ =
1
2 is the same as
δ = 0. The inequality δ < 0 is equivalent to θ < 12 and δ > 0 is equivalent
to θ > 12 .
In particular, since E(ζ) = 0 (because ζ is symmetric, see point 2 of
Remark 2.1), then we have δ = E(η) − E(ξ), hence θ = 12 is equivalent
to equality of means of these random variables. Again, the win probability
can be used also for the comparisons of means, namely if E(η) > E(ξ)
then P(η > ξ) > 12 and if E(η) < E(ξ) then P(η > ξ) <
1
2 .
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2. Suppose that the random variable ζ = η−ξ has a unique median δ0. Then,
again
P(η > ξ + δ0) =
1
2
.
Hence, θ = 12 is the same as the median of the difference of these random
variables being 0. A positive value of δ0 means the win probability is greater
than 12 , and negative δ0 means the win probability is less than
1
2 .
3. Suppose that there exists a real number δ such that ξ and η − δ have the
same distribution function F (·). This means that the distribution function
of η differs from the distribution of ξ only by a shift δ (like in Example
2.1). From point 3 in Remark 2.1 we get
P(η − δ > ξ) = 1
2
.
Thus, as in the examples above, θ = 12 means there is no shift in distri-
butions, whereas θ > 12 expresses a positive shift and θ <
1
2 expresses a
negative shift.
Remark 2.2. Example 2.3 shows that the win probability, θ, expresses, in some
sense, a comparison of locations of two distributions (like the mean difference,
the median of the difference of distributions or, in the case of shifted distribu-
tions, the shift). While the mentioned location comparison statistics are relevant
under some assumptions, the win probability can be defined in all cases, even
when the random variables are ordinal (comparison of the random variables is
defined, but the difference or sum is not). Also, from (3) in Example 2.2, we see
that the value of the win probability can depend on the scale parameters of the
distributions (the variances) as well, which shows that the win probability can
contain more information about the comparison of two distributions than just
the comparison of their locations. (In this case it contains information about
the spread of the distributions as well). Thus, the win probability gives more
complete information about closeness (equality) of distributions.
So far we have considered only random variables with continuous distribu-
tions. By modifying the definition (2) of a win probability we can have a general
definition of a win probability for all random variables.
Example 2.4. Consider the case of discrete random variables. Suppose that
the variable ξ is constant and ξ = 1, whereas the random variable η takes the
values η ∈ {1, 2} with corresponding probabilities p1 = 0.8, p2 = 0.2. Then
P(η > ξ) = P(η = 2) = 0.2.
So the win probability of the random variable η is less than 12 . But if we consider
the mean values of these variables we see that E(ξ) = 1 and E(η) = 1.2. Clearly,
the comparison of the win probability with 12 does not reflect the difference in the
mean values. The reason is the presence of ties, in other words the probability
of the event {ξ = η} is positive.
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To have consistency with the case of continuous random variables, where
P(η > ξ) > 12 reflected the fact of η being better than ξ, we will redefine the
win probability as
θ = P(η > ξ) + 0.5P(η = ξ). (4)
In Example 2.4 this redefined win probability would be
P(η > ξ) + 0.5P(η = ξ) = P(η = 2) + 0.5P(η = 1) = 0.6.
The important property in Remark 2.1 of identically distributed random vari-
ables having the win probability equal to 12 can be extended to the case of
non-continuous random variables as well. Denote ζ = η− ξ, which again will be
symmetric, that is, P(ζ < x) = P(−ζ < x) for all real values x. Hence from the
equality P(ζ > 0) + P(ζ < 0) + P(ζ = 0) = 1 we get 2P(ζ > 0) + P(ζ = 0) = 1,
and so P(η > ξ) + 0.5P(η = ξ) = 12 . Therefore θ =
1
2 and henceforth we will
use the general definition (4) of the win probability.
Remark 2.3. (Number Needed to Treat) Consider the case when the indepen-
dent random variables η and ξ are Bernoulli random variables with the proba-
bility of success being, correspondingly, p and q. Then, the win probability of η
against ξ would be
θ = P(η = 1, ξ = 0) +
1
2
(P(η = 0, ξ = 0) + P(η = 1, ξ = 1)) =
= p(1− q) + 1
2
(pq + (1− p)(1− q)) = p− q
2
+
1
2
.
Sometimes to characterize the benefit of an active treatment over a control an
NNT (number needed to treat) is calculated as the inverse of the absolute benefit
of intervention (see, for example, [Chatellier et al. (1996)])
NNT =
1
p− q .
Therefore, the NNT can be calculated using the win probability as follows
NNT =
1
2θ − 1 .
This formula can be used in a more general setting as well when η and ξ are
any two ordinal random variables. To calculate the estimated NNT we need to
replace the win probability with its estimate.
2.2 WP estimation
Consider the estimation problem of the win probability (4) for independent, in
general ordinal, random variables η and ξ using the samples (1). The events
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{ξ < η} and {ξ = η} are defined on the set of all possible values (ξ, η). Hence,
to estimate the probability (4) we can use the estimator
θˆN =
1
n1n2
n1∑
i=1
n2∑
j=1
(1I{y2j > y1i}+ 0.51I{y1i = y2j}). (5)
Here 1I is an indicator taking the value 1 if the corresponding specification is
satisfied, or 0 otherwise, and N = (n1 + n2). There are n1n2 possibilities of
comparing a component of Y2 to a component of Y1. For each comparison we
can have three results - a “win” for the active group if y2j > y1i, a “loss” if
y2j < y1i or a “tie” if y1i = y2j . The estimator (5) counts the number of wins
and one half of the number of ties over all possible combinations. The statistic
n1n2θˆN is known as the Mann-Whitney statistic. The estimator θˆN is a simple
frequency estimator to estimate the probability of success in a trinomial trial.
By the law of large numbers this estimator tends to the win probability θ, when
N → +∞. We call the estimator (5) the win proportion of the active group
against the placebo group. Modifying the win proportion we can write
θˆN =
1
n2
n2∑
j=1
1
n1
n1∑
i=1
(1I{y2j > y1i}+ 0.51I{y1i = y2j}) = 1
n2
n2∑
j=1
pj , (6)
where
pj =
1
n1
n1∑
i=1
(1I{y2j > y1i}+ 0.51I{y1i = y2j}), j = 1, · · · , n2. (7)
We call these quantities the individual win proportions of subject j in the active
group against the placebo group. In the same way, we can define the win
proportion of an individual i in the placebo group against the active group as
qi =
1
n2
n2∑
j=1
(1I{y2j < y1i}+ 0.51I{y1i = y2j}), i = 1, · · · , n1. (8)
It is easy to see that
θˆN =
1
n2
n2∑
j=1
pj = 1− 1
n1
n1∑
i=1
qi. (9)
Thus, the mean of the pj in (7) and the mean of the qi in (8), respectively
estimate the probabilities θ and (1− θ) (see (4)). Therefore the samples (1) of
independent, in general ordinal random variables, can be replaced by numeric
samples (see Appendix V in [Koch et al. (1998)])
Y 02 = (p1, p2, · · · , pn2), Y 01 = (q1, q2, · · · , qn1). (10)
The following theorem provides the asymptotic normality of the win proportion
as an estimator for the win probability.
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Theorem 2.1. If n1N → λ ∈ (0, 1), as N → +∞, and independent random
variables ξ and η have continuous distributions, then
√
N(θˆN − θ) =⇒ N
(
0,
σ210
λ
+
σ201
1− λ
)
, as N → +∞,
where
σ201 = Cov(1I(ξ < η), 1I(ξ′ < η)) = P(ξ < η, ξ′ < η)−P(ξ < η)2,
σ210 = Cov(1I(ξ < η), 1I(ξ < η′)) = P(ξ < η, ξ < η′)−P(ξ < η)2.
Here ξ, ξ′, η, η′ are independent. ξ, ξ′ have the same distribution and η, η′ have
the same distribution.
The proof of Theorem 2.1 is based on the theory of U-statistics developed
in [Hoeffding (1948)]. See also the Theorem 12.6 in [Van der Vaart (2000)]. For
generalizations see [Puri et al. (1971)].
The following theorem from [Koch et al. (1998)] gives estimates for the vari-
ances σ210, σ
2
01.
Theorem 2.2. Suppose that the random variables ξ and η are independent
and not constant. The estimator θˆN (see (5)) of the win probability (4) is
asymptotically normal with
θˆN − θ√
var(Y 02 )
n2
+
var(Y 01 )
n1
=⇒ N (0, 1), as n1 → +∞, n2 → +∞,
where var(Y 20 ) and var(Y
1
0 ) denote the estimates of the variances
var(Y 02 ) =
1
n2 − 1
n2∑
j=1
(pj − θˆN )2, var(Y 01 ) =
1
n1 − 1
n1∑
i=1
(qi − (1− θˆN ))2.
The proof of Theorem 2.2 can be found in [Brunner et al. (2000)], where the
theorem is formulated slightly differently (see Theorem 2.3). In Section 2.3, we
will show the equivalence of the formulations of these theorems.
Since from (9) we see that θˆN =
1
n2
∑n2
j=1 pj and 1 − θˆN = 1n1
∑n1
i=1 qi,
Theorem 2.2 allows construction of a confidence interval for the win probability
(4) using only the mean values and variances of the samples (10).
Example 2.5. Suppose that ξ ∼ N (2, 42) and η ∼ N (4, 22) are independent,
normally distributed random variables. The win probability is (see formula (3))
θ = 0.673. If we sample n1 = 100 numbers from ξ and n2 = 500 numbers
from η, then using (5) and Theorem 2.2 we can calculate the win proportion
θˆN = 0.64332 and its standard error se = 0.0357. The plot below shows the
convergence of the win proportion to the win probability when n1 = 100 is fixed
and n2 is changing from 1 to 500 in a single random sample.
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Figure 2.4: Convergence to win probability illustrated by a random sample
The left side of this figure corresponds to the case when n1 = 100 and
n2 = 1, hence the estimator (the win proportion) is far from the “unknown”
true parameter θ (the win probability). As we move to the right along the
horizontal axis, the sample size of the active group increases to 500, and the
rightmost part of the figure corresponds to the case of n1 = 100 and n2 = 500.
Therefore we see, that by keeping the sample size of the placebo group constant
and gradually increasing the sample size of the active group, the performance of
the win proportion improves, and it becomes closer to the win probability. The
same would be true if we were to fix the sample size of the active group and
gradually increase the sample size of the placebo group. This figure illustrates
the importance of the condition in Theorem 2.2 that the sample sizes of both
treatment groups need to tend to infinity.
2.3 Comparison to Wilcoxon rank-sum statistic
In this section we give details about the well known relationship between the
Mann-Whitney statistic described in Section 2.2 and the Wilcoxon two sample
rank-sum test. Consider the combined sample of length N = n1 +n2 of response
values across the two treatment groups
Y = (y11, · · · , y1n1 , y21, · · · , y2n2). (11)
Denote by (R11, · · · , R1n1 , R21, · · · , R2n2) the ranks of the sample Y. To get the
ranks we need to order the values yij increasingly. If all the values are different,
then the smallest value will have the rank 1 and the biggest value will have the
highest rank equal to N . If several values are equal, then each one of them
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will get the mean value of their ranks. For example, if we have the numbers
(3, 3, 2, 1, 4, 4, 4, 4, 4) then their ranks will be (3.5, 3.5, 2, 1, 7, 7, 7, 7, 7). Consider
the sum of the ranks of the second (active treatment) group
W =
n2∑
j=1
R2j .
This rank-based statistic is called the Wilcoxon rank-sum statistic. If we return
to our concepts of “winning” and “losing”, then, for the sample Y in (11) with
no ties, by subtracting 1 from the rank of the value, we will get the number
of wins of that value in the entire sample. That is, y2j wins against R2j − 1
numbers in the combined sample Y. For example, if the rank of a value is 5,
then this value wins against 4 other values. Now, if we introduce ranks in the
second group separately, (R˜21, · · · , R˜2n2), in the same way, R˜2j − 1 will show
the number of wins of the value y2j against its own group. Hence, if we take
the rank of the value in the entire sample and subtract the rank of the value in
its own sample , R2j − R˜2j , we will get the number of wins of that value against
the other group. Hence, if we take sum of the ranks of the second group in
the entire sample and subtract the sum of the ranks of the second group ranked
separately, then we will get the total number of wins of the second group against
the first group. Hence,
n1n2θˆN =
n2∑
j=1
(R2j − R˜2j). (12)
The sum of all ranks in the second group is always n2(n2+1)2 as it is the sum of
numbers 1, · · · , n2. Thus,
n1n2θˆN = W − n2(n2 + 1)
2
, (13)
which is the well known relationship between the Wilcoxon rank-sum statistic
W and the Mann-Whitney statistic.
Remark 2.4. Moreover, the relationship (13) (therefore also (12)) is true even
in the situations where there are ties. Indeed, a rank corresponds to the number
of wins + 1/2 the number of ties and added 1 in the corresponding set being
ranked. Therefore, assigning the mean value of the ranks to the equal values is
equivalent to adding the half of all ties to the sum of wins (see the definition in
(5)).
The following theorem is due to [Brunner et al. (2000)].
Theorem 2.3. Suppose that the random variables ξ and η are independent and
not constant. The estimator (5) of the win probability (4) is asymptotically
normal and
θˆN − θ
σˆN
=⇒ N (0, 1), as n1 → +∞, n2 → +∞,
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where the variance (or squared standard error) is equal to
σˆ2N =
1
n1(n1 − 1)n22
n1∑
i=1
(
R1i − R˜1i − R¯1 + n1 + 1
2
)2
+
+
1
n2(n2 − 1)n21
n2∑
j=1
(
R2j − R˜2j − R¯2 + n2 + 1
2
)2
,
and R¯1 =
1
n1
∑n1
i=1R1i and R¯2 =
1
n2
∑n2
j=1R2j.
Based on previous considerations, we can write the win proportion (see (7))
of each subject in the active group as pj =
R2j−R˜2j
n1
. On the other hand (see
(13)),
1
n1
(
R¯2 − n2 + 1
2
)
=
1
n1n2
n2∑
j=1
R2j − (n2 + 1)n2
2n1n2
=
1
n1n2
n2∑
j=1
(
R2j − R˜2j
)
,
and finally, using (12) and (6), we get
1
n1n2
n2∑
j=1
(
R2j − R˜2j
)
=
1
n2
n2∑
j=1
pj = θˆN ,
which means that
1
n2(n2 − 1)n21
n2∑
j=1
(
R2j − R˜2j − R¯2 + n2 + 1
2
)2
=
1
n2(n2 − 1)
n2∑
j=1
(
pj − θˆN
)2
.
Using the same arguments we get
σˆ2N =
1
n1(n1 − 1)
n1∑
i=1
(
qi − (1− θˆN )
)2
+
1
n2(n2 − 1)
n2∑
j=1
(
pj − θˆN
)2
,
which is the same variance as in Theorem 2.2. Thus, the classical relationship
between the Mann-Whitney statistic and Wilcoxon rank-sum statistic holds for
the tied values as well. The estimator of the win probability is
θˆN =
1
n2
n2∑
j=1
pj =
1
n1n2
n2∑
j=1
(
R2j − R˜2j
)
(14)
and the standard error of this estimate can be easily calculated using the means
and the variances of the sample (10).
Remark 2.5. Formula (14) and that for σˆ2N in Theorem 2.3 are computation-
ally less intense to implement than formula (6). Therefore, formula (14) is more
preferable. For formulas (12), (13) and (14) see the last paragraph of Appendix
VII: Computations in [Koch et al. (1998)].
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2.4 Hypothesis testing for win ratio
Alongside the win probability, which was introduced to characterize the differ-
ence in treatment effects in two treatment groups, we will consider also the the
win ratio which is the odds of winning of the active group against the placebo
group. The win ratio, κ, is defined as the win probability divided by the prob-
ability of loss (having ties equally divided between wins and losses), that is
κ =
θ
1− θ =
P(η > ξ) + 0.5P(η = ξ)
P(η < ξ) + 0.5P(η = ξ)
. (15)
A win ratio κ = 1 corresponds to the win probability being equal to θ = 12 .
Hence, κ > 1 corresponds to having a positive treatment effect. As we saw in
the previous examples, a positive mean difference corresponds to κ > 1. Now
consider the setting of time-to-event analysis.
Example 2.6. Consider survival times in two treatment groups when there is
no censoring. η is the survival time in the active group, whereas ξ is the survival
time in the placebo group. Suppose that these two independent random variables
follow exponential distributions with parameters ϕ and λ correspondingly,
η ∼ E(ϕ), ξ ∼ E(λ).
In other words, the hazard functions in the two groups are constant. In this case
the win probability of the active group is the probability of having longer survival
time in the active group. It can be seen that the win probability is
θ = P(η > ξ) =
λ
λ+ ϕ
=
1
ϕ
1
λ +
1
ϕ
=
E(η)
E(ξ) + E(η)
.
Hence, in this example the win ratio is the inverse of the hazard ratio,
κ =
1
(ϕ/λ)
=
E(η)
E(ξ)
=
λ
ϕ
.
This means that if the hazard ratio of active treatment versus placebo is smaller
than 1, then the win ratio is greater than 1. In other words, to have better
survival time the treatment group needs to have smaller hazard.
Example 2.6 shows that in the time-to-event setting without censoring and
with constant hazards, the win ratio is the same as the inverse of the hazard
ratio. This relationship between the win ratio and the hazard ratio remains true
under the more general proportional hazards assumption.
Example 2.7. Suppose again that η is the survival time in the active group,
whereas ξ is the survival time in the placebo group. Consider the survival func-
tions of these independent random variables,
Sξ(t) = P(ξ ≥ t), Sη(t) = P(η ≥ t).
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We assume that the hazard functions of these random variables are proportional
(the hazard ratio is constant), which means that Sη(t) = Sξ(t)
HR, where HR is
the hazard ratio of random variables η and ξ. Also in this case, θ = 11+HR and
κ = θ1−θ =
1
HR .
The treatment effect comparison can be tested by the following hypothesis
for the win ratio
H0 : κ = 1 against H1 : κ 6= 1. (16)
Theorems 2.2, 2.3 allow construction of an asymptotic test of level α ∈ (0, 1).
Indeed, for example from Theorem 2.3, we have
P(θ ∈ [θˆN − CασˆN , θˆN + CασˆN ])→ 1− α,
where Cα is the 1− α2 quantile of the standard normal distribution. Hence the
null hypothesis θ = 12 will be rejected if
1
2
/∈ [θˆN − CασˆN , θˆN + CασˆN ].
The asymptotic type I error of this test will be α. Since κ = θ1−θ , an estimator
for the win ratio is
κˆN =
θˆN
1− θˆN
.
Since the function f(x) = x1−x is an increasing function for x ∈ (0, 1), its
application to the asymptotic confidence interval of the win probability will
produce an asymptotic confidence interval for the win ratio as
[f(θˆN − CασˆN ), f(θˆN + CασˆN )].
2.5 Application of the win ratio
Consider a clinical trial where an objective is to compare the change from base-
line of the primary variable of interest in two treatment groups at a specific time
point, say, at the end of the trial. The primary variable can be a measurement
of a biomarker or a score of a questionnaire. If the subject dies during the trial,
then the change from baseline of the primary variable will be missing. The
assumption of missingness at random may be violated if there is a treatment
effect on mortality. A more specific example is given in Section 5, where the
score from a symptom questionnaire is described. There is an apparent corre-
lation between deterioration in symptoms and increased risk of death. Hence,
if the subject died before the end of the trial, then we need to incorporate this
information into the analysis of the primary variable, if we are interested to
measure the treatment effect as it is and not in a conditional setting of subjects
being alive. This can be done by considering the composite of the death and the
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change from baseline in the primary variable of interest, assigning the “worst”
change value to the subjects who die during the trial. In this case, combining
numerical values with death will convert the primary variable of interest into
an ordinal variable. Then the win ratio can be used to compare the treatment
effect in two groups.
To incorporate death into the analysis of the primary variable, we can choose
several strategies. Death is always considered worse than any measured change
from baseline. There are the following strategies to manage death:
1. Treat all deaths as equal, in other words, assign all deaths the same ordinal
value.
2. Ordering among deaths is defined based on a characteristic not directly
related to death, observed at or after baseline. For example, if there are
measurements of the same primary variable taken prior to death, then or-
dering among deaths can be done based on each individual’s last observed
value of change from baseline while alive, meaning that if a subject has
a higher change before dying than another subject who died, then this
subject will have a higher ordinal value than the other subject. In a set-
ting where there are no intermediate measurements taken, such a strategy
would correspond to a baseline carried forward approach. More generally,
any other measurement of a subject made during the trial, even if it is
done not on the primary variable of interest, can be used to define order-
ing among deaths. Any clinically justified combination of characteristics
measured at or after baseline could be used, as long as there is a sound
rationale for the importance of such factors.
3. Ordering among deaths is defined by characteristics that are directly re-
lated to the event of death. For example, ordering among deaths can
be done based on each individual’s observed survival time, meaning that
if a subject died later than another subject, then this subject will have
a higher ordinal value than the other subject. Another example is the
definition of the order based on the cause of death.
In Section 5 we will consider only the first two cases. In the first analysis
all deaths will have the same ordinal value. As an alternative approach we will
introduce ordering among deaths based on the last observed value of the same
primary variable while alive. All other intercurrent events, for example hospi-
talizations, happening between the baseline measurement and the measurement
done at the prespecified time point will not be included in the analysis and sub-
sequent values of the primary variable of interest will be used. This corresponds
to treatment policy strategy of handling intercurrent events, as described in
[ICH E9 (R1) (2019)]. The treatment policy strategy is based on the Intent to
Treat (ITT) principle. The purpose of the ITT principle is to measure the treat-
ment effect on the variable of interest directly, without using the information
of the intercurrent events. The treatment policy strategy cannot be applied to
missingness due to death, hence the composite strategy (combining the death
with observed values of the variable) to handle deaths is applied.
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We note that we have flexibility in combining the numeric value with the so
called “hard” clinical outcomes. Furthermore, this approach allows the specific
handling of all intercurrent events (not only death), as defined in [ICH E9 (R1) (2019)].
It is possible to combine intercurrent events by introducing prioritization. For
example, if a subject has an event after the baseline measurement and before
the end of the trial (the prespecified time point of the measurement), then the
occurrence of this event can be considered clinically more important than the
measurement of the primary variable at the end of the trial (which is done after
the mentioned event), even if observed. Therefore instead of the measurement
at the end of the trial, the occurrence of the intercurrent event can be used
to inform the estimation of the treatment effect. Returning to the example of
the EMPULSE trial described in the Introduction, if the subject experienced a
heart failure hospitalization before day 90, then the measurement of the symp-
toms score at day 90 is not used in the analysis. Instead the timing of HFH (if
only one HFH happened) or the total number of hospitalizations (if several HFH
happened) are considered clinically more relevant, and the composite strategy is
used to handle these intercurrent events. The prioritization of events is defined
as follows: deaths are assigned the worst category and the order among deaths
is introduced using the time to death (later is better). The next category of or-
dinal values is introduced using the total number of hospitalizations before day
90 (less is better) and subjects with one HFH during 90 days are compared us-
ing the time to HFH (latter is better). Finally, subjects who are alive at day 90
and did not have intercurrent HFH before that time point are compared based
on their observed change from baseline of KCCQ-CSS score. This approach
does not follow the treatment ploicy strategy, instead it uses the composite
strategy to handle the intercurrent events. The choice of strategy will shape
the definition of the estimand under trial, as defined in [ICH E9 (R1) (2019)].
The composite strategy of handling intercurrent events have more impact on
the estimand of the treatment effect on the KCCQ score (unlike the treatment
policy strategy), hence it does not measure the treatment effect “purely” on the
KCCQ score, but a type of “net clinical benefit”, which accounts for the most
clinically relevant outcomes that occur during the 90 days follow-up time.
3 Adjustment and stratification
3.1 Adjusted win probability
The theory of analysis of covariance of ordered categorical data is extensively
formulated in [Koch et al. (1982)] and [Koch et al. (1998)]. Here we will reit-
erate the main results of these articles.
In this section we will consider the scenario when the response variables are
observed with predictor values. For example, we could be interested in the effect
of the treatment having observed also some numeric baseline measurement of
individuals, for example, the age. Hence the observed samples are
(Y1, X1), (Y2, X2), (17)
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where Y1, Y2 are defined in (1) and
X1 = (x11, · · · , x1n1), X2 = (x21, · · · , x2n2).
The response variables Y1, Y2 are in general ordinal, whereas the predictor vari-
ables X1, X2 are often numeric. Here again using the individual win proportions
(as in (10)), we can replace the samples (17) with the samples
(Y 01 , X1), (Y
0
2 , X2),
where the individual proportions pj and qi are calculated using the formulas
(7),(8), without taking into consideration the values of the covariates. Consider
the mean values, the variances of the response variables and covariates, as well
as the covariances between the response variables and covariates
x¯1 =
1
n1
n1∑
i=1
x1i, x¯2 =
1
n2
n2∑
j=1
x2j , (18)
var(x1) =
1
n1 − 1
n1∑
i=1
(x1i − x¯1)2, var(x2) = 1
n2 − 1
n2∑
j=1
(x2j − x¯2)2,
Cov(x1, y01) =
1
n1 − 1
n1∑
i=1
(qi − (1− θˆN ))(x1i − x¯1),
Cov(x2, y02) =
1
n2 − 1
n2∑
j=1
(pj − θˆN )(x2j − x¯2).
Then, the adjusted win proportion can be defined as
βˆN = θˆN − x¯1 − x¯2var(x1)
n1
+ var(x2)n2
[
Cov(x1, y01)
n1
+
Cov(x2, y02)
n2
]
. (19)
Remark 3.1. For the randomized trial, βˆN is an estimator for θ, since the
expectation of the mean difference in covariates is zero, E(x¯1 − x¯2) = 0.
This estimator provides the win proportion of the active group against the
placebo group adjusted for the mean difference in covariates. As it is well
known (see, for example, [Koch et al. (1998)]), the adjustment for covariates
provides more powerful tests for the treatment comparison through the variance
reduction and accounts for possible random group differences in covariate values,
so that the observed treatment effect is not driven by the random difference in
covariates. In clinical trials the covariate often represents some numeric measure
on patients done at baseline. Denote the covariate dependent win probability
by β. The following theorem holds
Theorem 3.1. The adjusted win proportion βˆN is an asymptotically normal
estimator for the win probability β such that
βˆN − β
σˆβN
=⇒ N (0, 1), as N → +∞,
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and the applicable squared standard error is
(σˆβN )
2 =
var(Y 02 )
n2
+
var(Y 01 )
n1
−
[
Cov(x1,y01)
n1
+
Cov(x2,y02)
n2
]2
var(x1)
n1
+ var(x2)n2
.
Remark 3.2. Theorem 3.1 is applicable to any numeric covariate including
dummy covariates with the values 0 and 1. The method can be extended to the
case of ordinal covariates by replacing the mean difference (x¯1 − x¯2) by a win
proportion θˆN,x defined by pairwise comparisons of the values of covariates.
3.2 Stratified win probability
In the stratified analysis, we suppose that each treatment group is divided into
two separate subgroups, called strata (we are considering only the case of two
strata). The measurements of subjects in different strata have different distribu-
tions, even inside the same treatment group. Therefore the model assumes that
the measurements of each treatment group are characterized by two random
variables each (here as before, η denotes the active group, whereas ξ denotes
the placebo group)
(ξ, ξ′), (η, η′).
The samples from these random variables are denoted correspondingly (2 is for
the active group, 1 for the placebo group)
Y1 = (y11, · · · , y1n11), Y ′1 = (y′11, · · · , y′2n12), n1 = n11 + n12, (20)
Y2 = (y21, · · · , y2n21), Y ′2 = (y′21, · · · , y′2n22), n2 = n21 + n22, N = n1 + n2.
For each stratum, the win probability is defined as
θ = P(η > ξ) + 0.5P(η = ξ) and θ′ = P(η′ > ξ′) + 0.5P(η′ = ξ′). (21)
The stratified win probability is defined as
θstr = ωθ + (1− ω)θ′, w ∈ (0, 1).
The null hypothesis for the stratified analysis is
H0 : θ = 1
2
and θ′ =
1
2
against
H1 : θ 6= 1
2
or θ′ 6= 1
2
. (22)
Under the null hypothesis θstr = θ = θ′ = 12 regardless of the value of ω.
Sometimes instead of the weights we will specify only the coefficients ω1, ω2 per
stratum, and the weights can be calculated using the formula
ω =
ω1
ω1 + ω2
, 1− ω = ω2
ω1 + ω2
.
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For each stratum separately, we can construct the win proportions (5), de-
noted correspondingly by θˆN and θˆ
′
N . A general method of combining these
estimates is to use the weighted sum of the estimates in each stratum as
θˆstrN = ωθˆN + (1− ω)θˆ′N . (23)
The variance of the stratified estimator can be calculated using the formula
(since observations in different stratum are independent)
var(θˆstrN ) = ω
2var(θˆN ) + (1− ω)2 var(θˆ′N ). (24)
The variances of the win proportions inside each stratum can be estimated using
Theorems 2.2 and 2.3 as
var(θˆN ) = σˆ
2
N and var(θˆ
′
N ) = (σˆ
′
N )
2.
The weights can be estimated (see Appendix II in [Koch et al. (1998)]) using
the coefficients
w1 =
n11n12
n1
, w2 =
n21n22
n2
,
which will give the following estimates of the weights:
w =
1
n21
+ 1n22
1
n11
+ 1n12 +
1
n21
+ 1n22
, 1− w =
1
n11
+ 1n12
1
n11
+ 1n12 +
1
n21
+ 1n22
. (25)
Remark 3.3. If a balanced design between the treatment groups and the strata
is applicable, that is, n11 = n12 = n21 = n22, then both weights would be 0.5.
If the treatment group has the same proportion in both strata, n11n12 =
n21
n22
= n1n2 ,
that is, only balanced allocation of treatment within a stratum is present, then
w =
n1
n1 + n2
,
and so the larger stratum will get bigger weight.
Another possible choice of coefficients (see Section 4.3) is
w01 =
n11n12
n1 + 1
, w02 =
n21n22
n2 + 1
, (26)
which will give the van Elteren weight, denoted by w0.
Theorem 3.2. For the weights (25), (26) the following convergence holds
ZstrN =
θˆstrN − θstr√
var(θˆstrN )
=⇒ N (0, 1), nij → +∞, i = 1, 2, j = 1, 2.
Remark 3.4. The theorem above is true for a large family of weights depending
only on the sample size.
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3.3 Adjusted win probability with stratification
For a randomized trial, the null hypothesis for the adjusted win probability with
stratification is
H0 : β = 1
2
and β′ =
1
2
against
H1 : β 6= 1
2
or β′ 6= 1
2
, (27)
where β, β′ are the adjusted win probabilities per stratum. The observed sample
consists of response vectors and numeric covariate vectors for two treatment
groups (as in (17)), observed independently for both strata, denoted
Stratum I (Y1, X1), (Y2, X2),
Stratum II (Y ′1 , X
′
1), (Y
′
2 , X
′
2). (28)
Here, as usual, the first group is the placebo group and the second group is the
active group. As in the previous sections we need to replace the ordinal response
variables with individual win proportions.
Stratum I (Y 01 , X1), (Y
0
2 , X2),
Stratum II ((Y ′1)
0, X ′1), ((Y
′
2)
0, X ′2).
The individual win proportions are calculated for each stratum separately, dis-
regarding the values of covariates. There are several methods to estimate the
adjusted win probability with stratification. One way of achieving this is to
make covariate adjustment first, then use weights to combine these estimators.
The approach used in this section will follow [Koch et al. (1998)], where strat-
ification is performed first, separately for the crude win proportions and the
covariates using the same weights, and then the adjustment of stratified win
proportion with stratified covariate is made. Following Section 3.2 we can con-
struct the stratified win probability θˆstrN (see (23)). On the other hand, the
mean difference of covariates (see (18)) will serve as the statistic for comparison
of covariates between treatment groups
x¯ = x¯1 − x¯2, x¯′ = x¯′1 − x¯′2. (29)
Using the same weights as for the construction of θˆstrN , we can construct the
stratified mean difference of covariates
x¯strN = wx¯+ (1− w)x¯′. (30)
Therefore, an estimate for the adjusted win probability with stratification is
βˆstrN = θˆ
str
N −
x¯strN
var(x¯strN )
Cov(x¯strN , θˆstrN ). (31)
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Here var(x¯strN ) and Cov(x¯strN , θˆstrN ) are calculated as var(θˆstrN ) in (24)
var(x¯strN ) = w
2var(x¯N ) + (1− w)2 var(x¯′N ),
Cov(x¯strN , θˆstrN ) = w2Cov(x¯N , θˆN ) + (1− w)2Cov(x¯′N , θˆ′N ), (32)
while inside each stratum var(x¯N ), Cov(x¯N , θˆN ), var(θˆN ) are calculated as in
(18),(19). Below are the formulas for the stratum I
var(θˆN ) =
var(y01)
n11
+
var(y02)
n12
, var(x¯N ) =
var(x1)
n11
+
var(x2)
n12
,
Cov(x¯N , θˆN ) =
Cov(x1, y01)
n11
+
Cov(x2, y02)
n12
. (33)
The following result is from [Koch et al. (1998)].
Theorem 3.3. The following asymptotic result holds for a randomized trial
ZAdSN =
βˆstrN − βstr√
var(βˆstrN )
=⇒ N (0, 1), nij → +∞, i = 1, 2, j = 1, 2,
where βstr = wβ + (1− w)β′, w ∈ (0, 1) and
var(βˆstrN ) = var(θˆ
str
N )−
[Cov(x¯strN , θˆstrN )]2
var(x¯strN )
.
4 Win ratio and rank tests
In this section we consider several well known tests and compare them with
the tests described in previous sections. The test for non-adjusted win ratio
(see the Section 2.4) will be compared with the tests for the location problem
(Wilcoxon two sample rank-sum test and the Fligner-Policello test) and the win
probability itself will be compared with the Hodges-Lehmann estimator. The
test for the stratified win probability (see the Section 3.2) will be compared
with the Cochran-Mantel-Haenszel test and the test based on the adjusted win
probability with stratification (see the Section 3.3) will be compared with the
rank ANCOVA.
4.1 Tests for the location problem
Testing the hypothesis θ = 12 or, equivalently, κ = 1 is closely related to loca-
tion testing in a situation where the distribution function of the second sample
represents a shifted version of the distribution of the first sample (see Remark
2.2). Given the two samples (1), suppose that their distribution functions differ
only by a shift
Fξ(y) = P(ξ ≤ y), Fη(y) = P(η ≤ y) = Fξ(y − δ), for all y ∈ R.
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The hypothesis of interest is
H0 : δ = 0 against H1 : δ 6= 0. (34)
In the subsequent sections we will compare the estimators and the tests for the
win probability with the shift estimators and tests in the location problem.
4.1.1 Wilcoxon two-sample rank-sum test
The following theorem (see, for example, [Gibbons et al. (2010)], page 290) al-
lows construction of asymptotic tests for the hypothesis (34).
Theorem 4.1 (Wilcoxon). Under the null hypothesis δ = 0 the following con-
vergence for the Wilcoxon rank-sum statistic W =
∑n2
j=1R2j holds
ZN =
W − n2R¯N√
n1n2
N var(R)
=⇒ N (0, 1), as N → +∞,
where the ranks of the sample (11) are denoted by R = (R11, · · · , R1n1 , R21, · · · , R2n2).
The mean and the variance of all ranks are denoted correspondingly by R¯N =
1
N (
∑n1
i=1R1i +
∑n2
j=1R2j) and
var(R) =
1
N − 1
n1∑
i=1
(
R1i − R¯N
)2
+
1
N − 1
n2∑
j=1
(
R2j − R¯N
)2
.
Modifying the Z value from the Theorem 4.1 using the equality (see (13))
n1∑
i=1
R1i +
n2∑
j=1
R2j =
N(N + 1)
2
,
we can write
ZN =
W − n2N+12√
n1n2
N var(R)
. (35)
In the location problem the hypothesis δ = 0 is equivalent to θ = 12 , hence,
from Theorem 2.3 we can construct an asymptotic test based on the following
statistic
Z˜N =
θˆN − 12
σˆN
. (36)
Remark 4.1. For the Wilcoxon rank-sum test, the estimated variance in The-
orem 4.1 is only applicable under the null hypothesis where the distributions
of response variables for the two groups are identical (under the null hypothe-
sis in the specification (34)). More generally, the estimated variance shown in
Theorem 2.2, and in its equivalent formulation in Theorem 2.3, is applicable
regardless of whether the two groups have the same distribution and thereby is
applicable more broadly than under a null hypothesis for either θ = 12 or equality
of distributions.
25
Theorem 4.2 compares the Wilcoxon rank-sum test and the test based on the
win probability under the null hypothesis of the location testing specification
(34) (equality of distributions).
Theorem 4.2. Under the null hypothesis of (34), that is when the distributions
of random variables ξ and η are equal, the following relationship holds for the
statistics (35), (36)
Z˜2N
Z2N
=
var(R)
Nn1n2σˆ2N
=
1
n1n2
var(R)
N
var(Y 02 )
n2
+
var(Y 01 )
n1
.
Proof. The proof directly follows from Theorems 4.1 and 2.3, since from (13)
we have
θˆN − 1
2
=
W
n1n2
− n2(n2 + 1)
2n1n2
− 1
2
=
1
n1n2
(
W − n2(N + 1))
2
)
.
Hence from (36) we get
Z˜N =
1
n1n2σˆN
(
W − n2(N + 1))
2
)
.
Comparing the last expression with (35) we will get the proof of the theorem.
If n1 = n2 =
N
2 then
Z˜2N
Z2N
=
2
N2
var(R)
var(Y 02 ) + var(Y
0
1 )
.
Under the null hypothesis δ = 0 we have equality of distributions of random
variables ξ and η, and if additionally we suppose that this distribution is con-
tinuous then (see, for example, page 14, [Lehmann et al. (1975)])
var(R) =
N(N + 1)
12
,
then Theorem 4.2 can be simplified as follows
Z˜2N
Z2N
=
1
3
N + 1
N2
1
σˆ2N
=
N + 1
6N
1
var(Y 02 ) + var(Y
0
1 )
.
Remark 4.2. The quantity
Z˜2N
Z2N
can be greater or less than 1. Hence it is not
possible to say in advance which test will give smaller p-value.
4.1.2 The Hodges-Lehmann estimator of location shift
The previous section described a method of detecting a significant shift for
the location testing problem (34). Here we will discuss the Hodges-Lehmann
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estimator for the shift δ, which can be used to quantify the treatment effect,
while presenting the significance testing based on Theorem 4.1. In this section
we additionally require that the random variables ξ and η be numeric, to allow
calculations on the samples (1).
Consider all possible differences between the two groups in the sample (1)
Dji = Y2j − Y1i, j = 1, · · · , n2, i = 1, · · · , n1.
The median of all these n1n2 differences is called the Hodges-Lehmann estimator
(see, for example, [Lehmann et al. (1975)]). Hence if we order all the values Dji
increasingly and denote the ordered sample by D(k), k = 1, · · · , n1n2 then the
Hodges-Lehmann estimator is equal to
δˆ = D(k˜), k˜ =
n1n2 + 1
2
, n1n2 if is odd,
δˆ =
D(k˜) +D(k˜+1)
2
, k˜ =
n1n2
2
, otherwise.
It is well known that this estimator does not work well in the presence of ties.
Consider a simple model Y2 = (1, 1, 2) and Y1 = (0, 1, 2). The ordered differences
will be (−1,−1, 0, 0, 0, 1, 1, 1, 2) hence δˆ = 0. Which means that the Hodges-
Lehmann estimator does not detect the difference between these two samples.
However, if we calculate the win proportion of the second group against the
first group we will get θˆN = 0.61. Hence, the win proportion is a more adequate
measure of difference in this sample. It also provides a corresponding hypoth-
esis test result and requires fewer assumptions. Although there are methods
of constructing confidence intervals for the Hodges-Lehmann estimator (see, for
example, [Hollander et al. (1999)]), the hypothesis test is usually done using
the Wilcoxon test and is not based on the confidence interval itself which is
an additional disadvantage of the Hodges-Lehmann estimator. For the Hodges-
Lehmann estimator to have good properties, additional assumptions of η−ξ hav-
ing a continuous, symmetric distribution are needed ([Hollander et al. (1999)]).
4.1.3 The Fligner-Policello test
The Fligner-Policello test ([Fligner et al. (1981)]) is similar to the test based
on Theorem 2.2. It uses quantities called placements which are the same as
the individual win proportions (see (7), (8)) and the statistic for testing the
hypothesis is based on the samples (10).
Theorem 4.3 (Fligner-Policello). In the location testing problem suppose that
Fξ(·) and Fη(·) are different. In additional, require these distributions to be
symmetric. Denote by µξ and µη the medians (assumed unique) of distributions
ξ and η, respectively. Then, to test the hypothesis
H0 : µξ = µη against H1 : µξ 6= µη,
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the following statistic can be used
FN =
n1n2θˆN − n1n2(1− θˆN )
2
√
n22(n1 − 1)var(Y 01 ) + n21(n2 − 1)var(Y 02 ) + n1n2θˆN (1− θˆN )
, (37)
where θˆN is the win proportion (see (9)). Under the null hypothesis
FN =⇒ N (0, 1), as n1 → +∞, n2 → +∞.
Remark 4.3. Assumptions of uniqueness of medians and the symmetry of dis-
tributions is only needed to have the equivalence of conditions µη − µξ > 0 and
θ > 12 . If we test the hypothesis not on the medians but directly on the win
probability θ, then these conditions are not needed (as in Theorem 2.2).
From Theorems 4.1, 2.3 we have
ZN =
θˆN − θ√
var(Y 02 )
n2
+
var(Y 01 )
n1
=
θˆN − θ
σˆ2N
,
where the variances are estimated using the consistent estimators
var(Y 02 ) =
1
n2 − 1
n2∑
j=1
(pj − θˆn)2, var(Y 01 ) =
1
n1 − 1
n1∑
i=1
(qi − (1− θˆn))2.
Evidently if we consider the statistic where variances are estimated with the
coefficients 1/n instead of 1/(n− 1),
Z0N =
θˆN − θ√
1
n22
∑n2
j=1(pj − θˆn)2 + 1n21
∑n1
i=1(qi − (1− θˆn))2
, (38)
the asymptotic result of Theorem 2.2 will still be true.
Theorem 4.4. Under the null hypothesis θ = 12 , for the Fligner-Policello statis-
tic FN and the statistic Z
0
N defined in (38), the following relationship holds
(Z0N )
2
F 2N
≥ 1.
Proof. The proof immediately follows from (37). Indeed,
FN =
θˆN − 12√
1
n22
∑n2
j=1(pj − θˆn)2 + 1n21
∑n1
i=1(qi − (1− θˆn))2 + 1n1n2 θˆN (1− θˆN )
,
therefore
(Z0N )
2
F 2N
≥ 1 if θ = 12 .
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Remark 4.4. The result of Theorem 4.4 means that the test based on the statis-
tic Z0N for each value of the sample size N will give smaller p-value, than the
p-value based on the Fligner-Policello test. Thus, the former needs less evidence
to reject the null hypothesis than the Fligner-Policello test. For large values of
the sample size the tests based on ZN , Z
0
N and the Fligner-Policello test will
give similar results, since the difference in standard errors is 1n1n2 θˆN (1 − θˆN ),
which tends to 0 as n1 → +∞, n2 → +∞.
4.2 Regression on ranks
With respect to Section 3.1, in this section we will consider the situation when
a numeric covariate is present and the group comparison of ordinal response
variables should be adjusted for that covariate. [Koch et al. (1982)] describes
one way of conducting an adjusted comparison of groups by using the regression
on ranks. The observed sample is (17). The vector of response values Y =
(Y1, Y2) is replaced by the vector of ranks
R = (R11, · · · , R1n1 , R21, · · · , R2n2).
In the first step a simple linear regression is fitted for the pair (R,X), where
X = (x11, · · · , x1n1 , x21, · · · , x2n2) is the vector of covariates for the combined
two treatment groups. Denoting by R¯, X¯ correspondingly the means of the
ranks and the covariates, the estimates of the intercept and the slope of this
linear regression would be
ψˆ0 = R¯− ψˆ1X¯, ψˆ1 = Cov(R,X)
var(X)
.
In the next step we replace the ranks by their residuals after fitting the linear
regression described above
Rresij = Rij − (ψˆ0 + ψˆ1xij).
The formula for the residuals can be simplified as follows
Rresij = (Rij − R¯)− (xij − X¯)
Cov(R,X)
var(X)
. (39)
Then the computations for the Wilcoxon test (see Theorem 4.1) are applied to
the residuals in (39), and this means that the Z statistic in (35) is constructed
based on the residuals Rresij . On the other hand, if we calculate the sum of
residual ranks of the active group, then
n2∑
j=1
Rres2j =
n2∑
j=1
R2j − n2R¯− n1n2
N
(x¯2 − x¯1)Cov(R,X)
var(X)
,
hence, remembering also that θˆN − 12 = 1n1n2
(∑n2
j=1R2j − n2R¯
)
, we get
n2∑
j=1
Rres2j = n1n2
(
θˆN − 1
2
)
− n1n2
N
(x¯2 − x¯1)Cov(R,X)
var(X)
. (40)
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It is easy to see that
var(Rres) = var(R)− Cov(R,X)
2
var(X)
.
Therefore the Z value based on residuals will be (remembering that the sum of
residuals is always equal to zero)
ZresN =
∑n2
j=1R
res
2j√
n1n2
N var(R
res)
=
θˆN − 12 − 1N (x¯2 − x¯1)Cov(R,X)var(X)√
1
n1n2N
[
var(R)− Cov(R,X)2var(X)
] . (41)
Or, using the equation
θˆN − 1
2
=
1
n1n2
 n2∑
j=1
R2j − n2R¯
 = R2n2 −R1n1
N
, (42)
we can rewrite (41) as
ZresN =
1
N
R2n2 −R1n1 − (x¯2 − x¯1)Cov(R,X)var(X)√
1
n1n2N
[
var(R)− Cov(R,X)2var(X)
] . (43)
Equations (41) and (43) can be compared with the Z value under the null
hypothesis θ = 12 from Theorem 3.1
ZβN =
θˆN − 12 − x¯1−x¯2var(x1)
n1
+
var(x2)
n2
[
Cov(x1,y01)
n1
+
Cov(x2,y02)
n2
]
√√√√var(Y 02 )
n2
+
var(Y 01 )
n1
−
[
Cov(x1,y01)
n1
+
Cov(x2,y02)
n2
]2
var(x1)
n1
+
var(x2)
n2
.
Remark 4.5. The comparison of standard errors of win proportion and the
regression on the ranks is similar to the case of crude (non-adjusted) estimates in
Theorem 4.2; only a coefficient 1n1n2 is added. Formula (42), like formula (14),
is another computationally less intense method to calculate the win proportion.
4.3 The Cochran-Mantel-Haenszel test
In was shown in Section 2.3 that there is equivalence between the Mann-Whitney
U-statistic and the Wilcoxon rank-sum statistic. Both statistics can be gener-
alized to stratified analysis. For stratified analysis, the generalization of the
Mann-Whitney test is called the Cochran-Mantel-Haenszel test, and the gener-
alization of the Wilcoxon rank-sum test is called the Van Elteren test.
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Consider the problem of stratified analysis (20), (21). Unlike the null hy-
pothesis (22), a stronger condition will be subject to testing, that is, the equality
of distributions in each stratum,
H0 : Fξ(·) = Fη(·) and Fξ′(·) = Fη′(·), against
H1 : Fξ(·) 6= Fη(·) or Fξ′(·) 6= Fη′(·). (44)
As in Section 4.1.1 we can construct the win proportion and the corresponding
Z statistic (see Theorem 4.1) for each stratum separately. Denote by R the
vector of ranks of the sample Y = (Y1, Y2), and by R
′ the vector of ranks of the
sample Y ′ = (Y ′1 , Y
′
2). Then
Zn1 =
W − n12R¯n1√
n11n12
n1
var(R)
, Z ′n2 =
W ′ − n22R¯′n2√
n21n22
n2
var(R′)
. (45)
The idea for construction of the stratified statistic is to choose coefficients per
strata (w1, w2) and combine the estimates for each stratum using these coeffi-
cients
W str = w1W + w2W
′.
The Z statistic for the hypothesis testing can be obtained by combining the Z
values in (45) using the same coefficients
ZEltN =
W str − (w1n12R¯n1 + w2n22R¯′n2)√
w21
n11n12
n1
var(R) + w22
n21n22
n2
var(R′)
.
The van Elteren statistic (see, for example, page 145, [Lehmann et al. (1975)])
for testing the hypothesis in (44) uses the following coefficients
w1 =
1
n1 + 1
, w2 =
1
n2 + 1
.
Comparing to the van Elteren coefficients (26) that were used to estimate the
stratified win probability we get
n11n12w1 = w
0
1, n21n22w2 = w
0
2. (46)
Theorem 4.5 (van Elteren). Under the null hypothesis (44) and for the coef-
ficients defined in (46) the following convergence holds
ZEltN =⇒ N (0, 1), nij → +∞, i = 1, 2, j = 1, 2.
For the relationship of the van Elteren test and the Cochran-Mantel-Haenszel
test see [Landis et al. (1978)]. Here again, as in Theorem 4.2 we can compare
the statistic from this test with the statistic based on the win probability de-
scribed in Section 3.2. Using the equalities
θˆN − 1
2
=
1
n11n12
(W − n12R¯N ), θˆ′N −
1
2
=
1
n21n22
(W ′ − n22R¯′N ),
we get the following result
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Theorem 4.6. For the ZEltN statistic from the van Elteren test and the Z
str
N
statistic based on the stratified win probability with van Elteren weights, under
the null hypothesis of equality of distributions in each stratum, we have
(ZstrN )
2
(ZEltN )
2
=
1
n11n12
(w01)
2 var(R)
n1
+ 1n21n22 (w
0
2)
2 var(R
′)
n2
(w01)
2
var(θˆN ) + (w02)
2
var(θˆ′N )
.
Here w01, w
0
2 are the van Elteren coefficients defined in (26).
Remark 4.6. The comparison of Z statistics follows the same pattern as in
Remark 4.5, that is coefficients 1n11n12 and
1
n21n22
are added per stratum.
4.4 The rank ANCOVA
In this section we will compare the statistical hypothesis test based on the
adjusted and stratified win probability described in Section 3.3 with the rank
ANCOVA test. The rank ANCOVA was proposed in [Quade (1967)] (see also
Section 7.6, Rank Analysis of Covariance in [Stokes et al. (2012)], as well as
[Koch et al. (1982)],[Koch et al. (1990)]). The test based on the rank ANCOVA
approach is very similar to the test obtained from the regression on ranks in
Section 4.2. Here again, as the first step, a simple regression line will be fitted
for the ranks, but in the second step, instead of the Wilcoxon test, the van
Elteren test is performed, to account for the stratification as well.
The hypothesis to test is (27) while observing the samples (28). Introducing
the ranks R,R′ correspondingly for the combined samples Y = (Y1, Y2) and
Y ′ = (Y ′1 , Y
′
2). As in Section 4.2 we fit to the ranks R,R
′ their respective
(combined across treatment groups) covariate vectorsX,X ′ and derive (see (39))
the residuals Rres, (Rres)′ per each stratum. The van Elteren test, described
in the Section 4.3, can be applied to the residuals to test for treatment effect
difference across strata. Remembering that the sum of all residuals in a stratum
is zero, the van Elteren statistic will be
ZAN =
w1W
res + w2(W
res)′√
w21
n11n12
n1
var(Rres) + w22
n21n22
n2
var((Rres)′)
. (47)
Here w1 =
1
n1+1
and w2 =
1
n2+1
. The test based on this ZAN value will be called
rank ANCOVA test. The following result is from [Quade (1967)]
Theorem 4.7. The following asymptotic result holds
ZAN =⇒ N (0, 1), nij → +∞, i = 1, 2, j = 1, 2.
Here we can draw parallels between the rank ANCOVA test and the test
based on the adjusted win probability with stratification described in Section
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3.3. For each stratum separately we can write the formula (40)
W res =
n12∑
j=1
Rres2j = n11n12
(
θˆn1 −
1
2
)
− n11n12
n1
(x¯2 − x¯1)Cov(R,X)
var(X)
,
(W res)′ =
n22∑
j=1
(Rres2j )
′ = n21n22
(
θˆ′n2 −
1
2
)
− n21n22
n2
(x¯′2 − x¯′1)
Cov(R′, X ′)
var(X ′)
.
Using the notation (46) we set
w1W
res = w01
(
θˆn1 −
1
2
)
− w
0
1
n1
(x¯2 − x¯1)Cov(R,X)
var(X)
,
w2(W
res)′ = w02
(
θˆ′n2 −
1
2
)
− w
0
2
n2
(x¯′2 − x¯′1)
Cov(R′, X ′)
var(X ′)
.
Hence, dividing also the numerator and the denomination by (w01 + w
0
2) and
remembering that w0 =
w01
w01+w
0
2
is the van Elteren weight, we can simplify (47)
as follows
ZAN =
θˆstrN − 12 −
[
w0
n1
(x¯2 − x¯1)Cov(R,X)var(X) + (1−w
0)
n2
(x¯′2 − x¯′1)Cov(R
′,X′)
var(X′)
]
√
(w0)2
n1
[
var(R)− Cov(R,X)2var(X)
]
+ (1−w
0)2
n2
[
var(R′)− Cov(R′,X′)2var(X′)
] , (48)
here θˆstrN = w
0θˆn1 + (1− w0)θˆ′n2 . On the other hand, under the null hypothesis
of adjusted win probability with stratification being β = 12 , we derive from
Theorem 3.3 (see formulas (29)-(33))
ZAdSN =
θˆstrN − 12 − x¯
str
N
var(x¯strN )
Cov(x¯strN , θˆstrN )√
var(θˆstrN )− [Cov(x¯
str
N , θˆ
str
N )]
2
var(x¯strN )
. (49)
Remark 4.7. To compare the Z values from (48) and (49), we see the follow-
ing differences. First, the rank ANCOVA approach uses combined estimates of
variances across treatment groups in each stratum, while the test based on the
adjusted win probability with stratification uses pooled estimates of variances.
Second, the rank ANCOVA approach performs adjustment by the numeric co-
variate first, then combines estimates across strata, whereas in the win probabil-
ity approach the non-adjusted win proportion, the covariates are combined across
strata then the adjustment is performed. Overall, both methods provide similar
statistical tests, while the win probability approach provides also treatment ef-
fect measure with its confidence interval which corresponds to the mentioned
statistical test.
5 Applications to a clinical trial data
In this section we will apply the win ratio and rank ANCOVA methodology
described in previous sections to the DAPA-HF trial data. Specifically, the
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data from a PRO (patient reported outcome) questionnaire, which measures
heart failure (HF) related symptoms, will be used.
5.1 Kansas City Cardiomyopathy Questionnaire (KCCQ)
The KCCQ is a self-administered disease specific instrument for patients with
HF (see [Green et al. (2000)], [Spertus et al. (2005)]). The KCCQ consists of
23 questions measuring, from the patients perspectives, their HF-related symp-
toms, physical limitations, social limitations, self-efficacy, and health-related
quality of life over the prior 2 weeks. All items are measured on a verbal re-
sponse scale with 57 response options. There are five individual subscales, and
all, except the symptom stability question and self-efficacy subscale, are aggre-
gated into a clinical summary score (CSS) (average of the physical limitation
score and total symptom score) and overall summary score (OSS) (average of
the physical limitation score, total symptom score, quality of life score and social
limitation score) (Figure 5.5).
Figure 5.5: Mapping of KCCQ items and scores to conceptual domains and
summary scores
Scores for each subscale are standardized to range from 0 to 100 with higher
scores indicating a better outcome. The KCCQ is scored by assigning each
response an ordinal value, beginning with 1 for the response that implies the
lowest level of functioning, and summing items within each domain. Scale scores
are transformed to a 0 to 100 range by subtracting the lowest possible scale score,
dividing by the range of the scale and multiplying by 100. For the analysis we
will use only the KCCQ-TSS (Total Symptoms Score) which is the average of
the symptoms frequency score and the symptoms burden score (see Figure 5.5.)
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5.2 DAPA-HF trial design
DAPA-HF was an international, multicentre, parallel group, event-driven, ran-
domized, double-blind, clinical trial in patients with chronic HFrEF (heart fail-
ure with reduced ejection fraction), evaluating the effect of dapagliflozin 10mg,
compared with placebo, given once daily, in addition to standard of care, on
the risk of worsening heart failure and cardiovascular death (registration num-
ber NCT03036124 in ClinicalTrials.gov). The total number of subjects was
N = 4744, of which n2 = 2373 were randomized to the dapagliflozin group,
n1 = 2371 to the placebo group. In the hierarchical testing procedure for end-
points under strong type I error control, the third secondary endpoint was the
change from baseline measured at 8 months in the KCCQ-TSS. The KCCQ-TSS
was assessed at baseline (randomization) and at 4 and 8 months after random-
ization and was analyzed as a composite, ordinal variable, incorporating the
vital status of subjects at 8 months along with a change in score from base-
line to 8 months in surviving subjects, while missingness for reasons other than
death was imputed using the multiple imputation method under the Missing At
Random assumption. The treatment effect was estimated using the win ratio
appraoch. The analysis yielded a win ratio of 1.18 (1.11, 1.26), p < 0.0001 (see
[McMurray et al. (2019)].) The win ratio was calculated using the adjusted win
probability approach with stratification, as described in Section 3.3. The sta-
tistical test of the null hypothesis, on the other hand, was performed using the
rank ANCOVA approach described in Section 4.4. In the subsequent sections
we give more details on methods for calculating the win ratio and the statistic
used for the hypothesis testing.
5.3 Complete case analysis
In total N = 3891 subjects had the KCCQ change from baseline at month 8
measured, i.e. both baseline value and value at month 8 was available (n1 = 1965
in the placebo group and n2 = 1926 in the dapagliflozin group). Table 5.1 gives
the details of the mean difference analysis of KCCQ-TSS scores between the
two groups.
Figure 5.6 shows the histograms of the change from baseline at month 8
in KCCQ-TSS score. They indicate that it is reasonable to assume normality
of the underlying distributions in both treatment groups for the change from
baseline of the KCCQ score. Therefore, a t-test can be performed to compare
the treatment effect in two groups.
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Table 5.1: Change from baseline at month 8 in KCCQ-TSS, unadjusted complete
case analysis without stratification
Treatment Comparison
Dapa Placebo
n2 = 1926 n1 = 1965
mean (sd) 6.1, (18.6) 3.3, (19.2)
mean diff (CI), t-test 2.8 (1.6, 4), p < 0.0001
WR (CI), non-parametric test 1.21 (1.13, 1.3), p < 0.0001
parametric WR 1.18
Figure 5.6: Histograms of change from baseline at month 8 in KCCQ-TSS by
treatment group
The estimates presented in Table 5.1 are for the win ratio (15) and the p-
value corresponds to the hypothesis test (16). Assuming normal distributions
and estimating the mean and standard deviation of these distributions from the
data (see Table 5.1), we get ξ ∼ N (3.3, 19.22) and η ∼ N (6.1, 18.62). Here
again η denotes the random variable describing KCCQ-TSS in the active (da-
pagliflozin) group, whereas ξ denotes the KCCQ-TSS in the placebo group. This
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means that we can calculate the parametric estimate (based on the form of the
distribution) of the win ratio using the formula (3) for the win probability. A
non-parametric estimate for the win ratio can be constructed using formula (5),
while the confidence interval and the p-value of the null hypothesis that the
win ratio equals to 1 can be calculated using Theorem 2.2. The results are
summarized in Table 5.1.
Below we provide the two-way ANCOVA analysis for the change from base-
line at month 8 in KCCQ-TSS adjusted for the baseline KCCQ-TSS score and
including the type 2 diabetes status at baseline as a stratification factor (see
[Kosiborod et al. (2019)]). The least-square means and the corresponding test
of their equality are summarized in Table 5.2.
Table 5.2: Change from baseline at month 8 in KCCQ-TSS, adjusted complete
case analysis with stratification
Treatment Comparison
Dapa Placebo
n2 = 1926 n1 = 1965
lsmean (stderr) 6.0, (0.37) 3.4, (0.37)
lsmean diff (CI), t-test 2.8 (1.9, 3.6), p < 0.0001
WR (CI), adj-str test 1.2 (1.12, 1.28), p < 0.0001
5.4 Handling missingness for reasons other than death
Missing data was categorized into two categories; due to death and not due to
death. Any KCCQ-TSS value which was not missing due to death was imputed
using multiple imputation (see [Rubin (2004)]) under the assumption that it was
Missing At Random (MAR). The imputation was done sequentially, as described
below.
First, all occurrences of missing data where there were observations made
after the missing data point (non-monotone missingness), were replaced in multi-
ple imputation datasets, using Markov Chain Monte Carlo with separate chains
per subject. In this imputation model, only randomization stratum, treatment
arm and observed KCCQ values were included.
For missing data where there were no observations made after the missing
data point (monotone missingness), a predictive mean matching imputation ap-
proach was applied using the posterior predictive distribution. A linear regres-
sion model was estimated, based on observed data and including randomization
stratification factor, treatment arm, previously observed values and number of
preceding heart failure hospitalizations, as predictors. New predictions were ob-
tained for the observed data points, using the estimated regression coefficients.
The same linear model was then used to find the posterior predictive distribution
of the regression coefficients. From this distribution, new regression coefficients
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were randomly drawn and, using the newly drawn regression coefficients, pre-
dicted values were obtained for the missing data points. For each missing data
point, its five closest neighbors were identified among the predicted values of
the originally observed data points. An imputation value was randomly selected
from these five values. This was done sequentially, starting at the earliest time
point and progressing until the last time point had been imputed for all subjects
with missing data, including imputations made along the way. This procedure
is done multiple times, creating multiple imputation datasets. The analysis re-
sults on imputed data are then pooled across imputation datasets, taking into
account both within-dataset variation and between-dataset variation.
Remark 5.1. A simple method of handling missingness for reasons other than
death would be to apply a sequential monotone method beginning with imputing
missing data for a first post-baseline visit and subsequently proceeding to impute
a second post-baseline visit from preceding observed or imputed values. Alterna-
tive methods to multiple imputation method not requiring the missing at random
assumption are described in [Fan et al. (2016)]. One other possibility (imple-
mented in [Kawaguchi et al. (2015)]) is to manage missing values as being tied
with all other values, and this way of proceeding is applicable to both deaths and
missing values for other reasons; and its invocation enables assessment of treat-
ment comparisons in an environment which is reasonably neutral with respect
to deaths as well as other missing values and also does not involve a missing at
random assumption.
5.5 Incorporating death
In Section 2.5 we discussed three strategies of incorporating deaths into the
analysis of symptom scores. Here we will deal with only the first strategy,
that is, subjects having experienced death before the assessment date of the
symptom score will be assigned the same worst (lowest) ordinal value. The
missing values not due to death were considered as missing at random and were
imputed using the multiple imputation method. Hence, the number of non-
missing change from baseline values at month 8 was 4744 minus the number of
deaths prior to that time point. Overall 257 deaths happened prior to month
8 (121 in the dapagliflozin group and 136 in the placebo group), hence making
the number of available changes from baseline (including the imputed values
of KCCQ-TSS) 2235 in the placebo group and 2252 in the dapagliflozin group.
Table 5.3 summarizes the results for the adjusted win ratio estimation with
stratification (see Section 3.3) and the test based on the rank ANCOVA (see
Section 4.4).
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Table 5.3: Adjusted analysis of the composite of KCCQ-TSS and death
Treatment Comparison
Dapa Placebo
n2 = 2373 n1 = 2371
WP 0.54 0.46
WR (CI) 1.18 (1.11, 1.26)
Adj-str WR test p < 0.0001
rank ANCOVA p < 0.0001
5.6 Discussions
In Section 2.5 we described several strategies to handle intercurrent events in
the analysis of change from baseline in the symptoms scores. In the win ratio
analysis in the DAPA-HF study, all intercurrent events, except deaths, were
handled using the treatment policy strategy, i.e. these events are disregarded
and subjects were followed as if the events had not occurred. As is described
in [ICH E9 (R1) (2019)], the treatment policy strategy cannot be implemented
for intercurrent events that are terminal events, since values for the variable
after the intercurrent event do not exist. Hence the composite strategy was
used to handle deaths. If we were to combine all HFH intercurrent events in
an endpoint, that would have more impact on the estimand, and instead of
estimating the effect of the treatment on the change in symptoms score we
would be estimating a “net clinical benefit”. The same would be true if we were
to incorporate death into the composite endpoint using scenario 3 of Section
2.5, which uses a comparison of deaths based on a characteristic directly related
to the event of death, for example the timing of death. Therefore only scenarios
1 and 2 were considered in the DAPA-HF study. By defining an order between
deaths based on a characteristic not directly related to the event of death, a
separation of the effect of the treatment on the death and on the symptoms
scores was done, so the effect on symptoms scores was not driven by the effect
of the treatment on risk of death.
The results presented in Tables 5.1, 5.2 and 5.3 show that the estimated
treatment effect on the symptoms score is robust, that is, it is not contingent
upon the choice of statistical methods and assumptions. The estimation of the
adjusted win ratio with stratification does not have any distributional assump-
tions, and the corresponding statistical test is similar to the rank ANCOVA
test. In the complete case analysis for the change from baseline, the mean
difference is an appropriate method to describe the difference in distributions,
since Figure 5.6 demonstrates the normality (hence symmetry) of underlying
distributions. Because of normality of underlying distributions, the estimated
non-parametric win ratio and the parametric win ratio in Table 5.1 are almost
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the same. In a setting where the underlying distributions are not normal, the
non-parametric win ratio estimate will still be valid. Moreover, combining the
numerical changes from baseline with death as the worst possible change trans-
forms the variables of interest into ordinal variables, and the win ratio is, again,
an appropriate method to test the difference in distributions. The win ratio in
Table 5.2 which is a complete case analysis and the win ratio in Table 5.3 which
is an imputation based analysis (with multiple imputation of missing data not
due to death and including the events of death), show that although adding
deaths into the analysis yields a more complete estimate of the treatment effect,
in a more realistic setting where subjects can die, the magnitude of treatment
effect is the same, which confirms that the effect in KCCQ-TSS scores is not
driven by the treatment effect on reducing mortality, which was observed in the
trial, as shown in [McMurray et al. (2019)]. The method of handling deaths in
Table 5.3 corresponds to scenario 1, that is, all deaths were treated equal. This
analysis was the sensitivity analysis in the DAPA-HF trial, whereas the primary
method of analysis was based on the scenario 2, where an order between deaths
was introduced based on the last change from baseline of the subject while alive.
That method yields the same estimate and the confidence interval, confirming
that, in this case, the handling of deaths does not change the treatment effect
estimate of KCCQ-TSS scores. This was due to the fact that although there
was an effect in all-cause mortality for the full duration of the study, at month
8 the number of deaths was small and was balanced in both treatment groups.
In case where the difference in number of deaths in both treatment groups is
clearly different at the timepoint of measurement, the handling of death can
have more influence on the estimated treatment effect.
One potential drawback of the win ratio (and the associated win probability)
is that the statistical interpretation of this measure is not as straightforward as,
say, a difference in means. Both measures are essentially group-level estimates;
making inference regarding the similarity of two independent groups, with re-
spect to the location of their distributions. When looking at the difference in
means, this is interpreted as the average difference in locations, assuming that
the underlying variable is continuous and normal, and that there are no intercur-
rent events which influence the estimand (what is being estimated) if they are
ignored. Average change in each group of symptoms scores is easy to interpret
since it has the same unit of measurement as the symptoms score itself, meaning
that participants of each group would expect to have approximately the same
change in symptoms as the average of their group. If the underlying data is
not continuous, or there are major departures from normality, a non-parametric
approach is more appropriate. The non-parametric win ratio can also easily
incorporate a composite strategy for handling intercurrent events (e.g. deaths).
The interpretation of the win ratio is that it is the average odds of the win
probability, i.e. the chance of one group having a “greater benefit” compared to
the other. The estimated number of subjects who need to be treated to observe
such a benefit, can be calculated and expressed using the win probability. This
would amount to deriving a Number Needed to Treat (NNT) based on the win
ratio.
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To better understand the treatment effect that corresponds to the win ratio
of 1.18 (or, equivalently, the win proportion 0.54, see Table 5.3), we can calculate
the estimated NNT as defined in Remark 2.3. The win proportion equal to 0.54
will yield an NNT = 12∗0.54−1 = 13 (to get an integer in calculating the NNT we
always round up fractional numbers), which can be interpreted as 13 subjects
need to be treated by dapagliflozin in addition to standard of care, compared
to being treated with standard of care alone, to have one subject with better
benefit in symptoms. It is important to note that the win ratio is calculated
based on the change from baseline. The least-squares mean of the change from
baseline in the placebo group is 3.4 (see Table 5.2), which shows that in the
placebo group, as well as in the dapaliflozin group, there is an improvement in
symptoms. Hence, to be precise, 13 subjects need to be treated by dapagliflozin
to have one subject with better improvement in symptoms than they would
have if they were treated only by standard of care.
Table 5.4: NNT based on the win probability
Comparison NNT
Win ratio Win prob
1.05 0.5121951 41
1.1 0.5238095 21
1.15 0.5348837 15
1.18 0.5412844 13
1.2 0.5454545 11
1.25 0.5555556 9
1.3 0.5652174 8
1.35 0.5744681 7
1.4 0.5833333 6
1.45 0.5918367 6
1.5 0.6 5
2 0.6666667 4
3 0.75 2
- 1 1
6 Conclusions
The win ratio is a general method of comparing locations of distributions of
two independent, ordinal random variables. Under minimal assumptions, an
asymptotically normal estimator for the win ratio can be derived. Stratification
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and numeric covariate adjustment can be made using simple modifications of
the estimator for the crude win ratio. It was shown that the win ratio and
its modifications for stratified analysis, adjusted analysis and adjusted analysis
with stratification give tests that, under the null hypothesis, are correspondingly
equivalent to the Wilcoxon rank-sum test or to the Fligner-Policello test, linear
regression testing on the ranks, van Elteren or Cochran-Mantel-Haenszel test
and the rank ANCOVA test, with the advantage that the win ratio itself provides
an interpretable treatment effect measure. Hence, the unified method of the win
ratio described in the present work can be used instead of several different tests
both for treatment effect estimation and for the corresponding treatment effect
difference testing.
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